ArticleBiomedical optics express2026
Defining the optimal imaging time point for fluorescence-lifetime-based tumor identification using the non-targeting near-infrared dye indocyanine green and post-processed high-dynamic-range images.
Article in Biomedical optics express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indocyanine green (ICG) is used for tumor visualization using fluorescence-intensity imaging, but false-positive signals are common. Fluorescence-lifetime-based tumor identification may overcome this limitation by measuring the time behavior of fluorescent light. However, the optimal time point for fluorescence lifetime imaging after the intravenous administration of ICG is yet to be defined. In this paper, the in vivo time course of ICG is investigated in syngeneic tumor-bearing mice using a novel macroscopic fluorescence lifetime camera. High-dynamic-range images were generated through post-processing, investigated, and subsequently applied for time-domain intensity and lifetime image analysis. The results indicate that fluorescence lifetime imaging may provide higher accuracy in tumor identification than intensity-based imaging, but the optimal imaging time point appears to require a 24-48 hour interval after intravenous injection, similar to intensity measurements. However, earlier time points might be of interest to investigate for liver and intestinal tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.